![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
(40) Changes in Brain and Cerebrospinal Fluid Using the Novel 
-Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the Rat
Departments of In Vivo Neuroscience (J.D.B., M.T.J., F.O., J.R.A.), Medicinal Chemistry (I.C., T.H.), Drug Metabolism and Pharmacokinetics (M.R., P.M.-G., C.P.), and Molecular and Cellular Neuroscience (M.S.S.), The Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Terlings Park, Harlow, Essex, United Kingdom
Received December 21, 2005; accepted January 26, 2006.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
peptides are one of the hallmarks of Alzheimer's disease. These A peptides are produced by the final proteolytic cleavage of the amyloid precursor protein by the intramembraneous aspartyl protease 
-secretase. Thus, one approach to lowering levels of A has been via the inhibition of the -secretase enzyme. Here, we report a novel, bioavailable -secretase inhibitor, N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) that displayed oral pharmacokinetics suitable for once-a-day dosing. It was able to markedly reduce A in the brain and cerebrospinal fluid (CSF) in the rat, with ED50 values of 6 and 10 mg/kg, respectively. Time-course experiments using MRK-560 demonstrated these reductions in A could be maintained for 24 h, and comparable temporal reductions in rat brain and CSF A(40) further suggested that these two pools of A are related. This relationship between the brain and CSF A was maintained when MRK-560 was dosed once a day for 2 weeks, and accordingly, when all the data for the dose-response curve and time courses were correlated, a strong association was observed between the brain and CSF A levels. These results demonstrate that MRK-560 is an orally bioavailable -secretase inhibitor with the ability to markedly reduce A peptide in the brain and CSF of the rat and confirm the utility of the rat for assessing the effects of -secretase inhibitors on central nervous system A(40) levels in vivo.
proteins A(1-40) and (1-42), cleavage products of the APP of which the majority is the more fibrillogenic (1-42) form (Selkoe, 2001
). These observations, along with a number of mutations in the APP gene that lead to early onset familial AD, give evidence of the direct involvement of aberrant APP processing in AD (Hardy, 1997).
Consequently, much effort has focused on ways to inhibit the production of A. The enzymes responsible for processing APP into A are the aspartyl proteases, -site APP cleaving enzyme (-secretase) and -secretase (Churcher and Beher, 2005). Although an attractive target for drug discovery, inhibition of -secretase has proved challenging in terms of identification of small molecules for therapeutic use (Selkoe and Schenk, 2003; Middendorp et al., 2004). An alternative strategy has been to inhibit -secretase, an enzyme complex composed of at least four different protein subunits: presenilin (an aspartyl protease, mutations of which are associated with familial AD), nicastrin, APH-1, and PEN-2. -Secretase is responsible for the intramembraneous proteolytic cleavage of the C-terminal fragment of APP, resulting in mainly A(40) or A(42) production (for review, see Selkoe and Schenk, 2003; Haass, 2004).
There have been a number of reports of novel, bioavailable -secretase inhibitors that have been tested in both transgenic and nontransgenic animal models (Dovey et al., 2001; Lanz et al., 2003, 2004; Anderson et al., 2005; Barten et al., 2005; Best et al., 2005; Grimwood et al., 2005). From these studies, it was established that -secretase inhibitors are able to reduce A in both overexpressing and physiological models. The -secretase inhibitor LY-411575 was able to reduce A in both the transgenic Tg2576 mice (which harbor the Swedish familial AD APP mutation) (Lanz et al., 2004) and the physiological rat model (Best et al., 2005). Furthermore, BMS-299897 was reported to be able to reduce A in Tg2576 mice (Barten et al., 2005), APP-YAC mice (which overexpress the normal human APP gene), and guinea pigs (Anderson et al., 2005).
We have previously reported a potent novel class of bioavailable -secretase inhibitor, MRK-560 (compound 32; Churcher et al., 2006). In SH-SY5Y neuroblastoma cells, this compound inhibited the production of A(40) and A(42) with similar in vitro IC50 values in the range of 0.65 nM and reduced A(40) in the APP-YAC mouse model with an ED50 of 1.2 mg/kg. The aim of the present study was to further characterize the in vivo effects of MRK-560 in the rat and to extend these investigations to examine the effects of MRK-560 on CSF A(40) concentrations to determine whether changes in CSF A(40) reflect changes in the brain A(40).
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Chemistry. MRK-560 (Fig. 1) was prepared by methods described previously (Churcher et al., 2006).
|
Pharmacokinetic Analysis of MRK-560. Male Sprague-Dawley rats (350 g; Charles River, Manston, Kent, UK) had their food withdrawn overnight. MRK-560 was administered as a bolus injection of 1 mg/kg intravenously [1 ml/kg as a solution in 3:1 polyethylene glycol 300/water (v/v)] and orally (5 ml/kg as a suspension in 0.5% methylcellulose in water). Serial blood samples were collected at specified time points up to 24 h after dosing. Plasma was separated by centrifugation, and the samples were stored at -80°C before analysis. The plasma samples were thawed, processed, and analyzed as described previously (Best et al., 2005).
Dosing and Tissue Collection. Male Sprague-Dawley rats (250-300 g; Charles River) were dosed orally as a suspension in 0.5% methylcellulose at 1 ml/kg. In the first study, a dose response was conducted at 8 h after administration of MRK-560 (1, 3, 10, 30, and 100 mg/kg p.o.). In the second study, animals received a single dose or were dosed once a day for 2 weeks with 45 mg/kg, and tissue was collected at 4, 8, 16, and 24 h after the final dose. Animals were anesthetized using isoflurane. CSF was removed by puncturing the cisterna magna with a 21-gauge butterfly cannula, and then they were euthanized by decapitation. Brains were removed and, along with the CSF, immediately frozen on dry ice and stored at -80°C until use. CSF samples with visible blood contaminants were discarded. After decapitation, blood was collected into EDTA-coated Vacutainers (Becton Dickinson UK Ltd., Oxford, UK) and spun at 3000 rpm for 10 min; plasma was collected, and both samples were frozen at -80°C until use. The plasma and brain samples were thawed, processed, and analyzed for drug concentrations as described previously (Best et al., 2005).
Tissue Sample Preparation for A(40) Measurement. The frozen brains were homogenized in 10 volumes (w/v) of 0.2% Diethylamine containing 50 mM NaCl, pH 10, and protease inhibitors, and then centrifuged at 355,000g, 4°C, for 30 min (Optima MAX series ultracentrifuge; Beckman Coulter, Fullerton, CA). The resulting supernatant was retained as the soluble fraction and neutralized by addition of 10% 0.5 M Tris-HCl, pH 6.8. Samples were frozen at -80°C awaiting analysis. There was no significant difference in A levels between this extraction method and the guanidinium-HCl extraction method, as might be expected in normal physiological, plaque-free animals (data not shown; Lanz et al., 2004). Before analysis, the CSF was thawed and centrifuged at 2300g, and the supernatant was diluted 1:4 with phosphate-buffered saline, 2% bovine serum albumin, and 0.5% Tween 20 plus protease inhibitors.
Measurement of A(40). The monoclonal antibody G2-10 (Ida et al., 1996) was used with biotinylated antibody 4G8 (Kim et al., 1988) to detect A peptides in solution ending at residue 40, with negligible cross-reactivity. These species, referred to as A(40), reflect subpopulations of peptides with heterogeneous N termini encompassing at least the 4G8 epitope at residues 17 to 24. Analysis of the samples was performed using the Meso Scale Discovery Sector Imager 6000 (Meso Scale Discovery, Gaithersburg, MD), as described previously (Best et al., 2005).
Data and Statistical Analyses. Groups were analyzed using two-way and one-way analysis of variance and, where appropriate, post hoc Dunnett's t test with vehicle/control group or Bonferroni's t test between experimental groups applied (Prism 3.03; GraphPad Software Inc., San Diego, CA). For time courses, A(40) level reductions were integrated using the area under the curve trapezoid rule.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
(40). To determine the effect of MRK-560 in the rat, a dose-response experiment was performed 8 h after oral dosing, which was deemed to be the most favorable time point from the oral pharmacokinetic profile (Fig. 2B). The plasma and brain concentrations of MRK-560 increased in a dose-dependent manner over the dose range tested (1-100 mg/kg; Fig. 3, A and B). Moreover, the plasma drug concentrations in this particular study (0.21 ± 0.025 µM) were comparable with those observed in the initial study (0.18 ± 0.036 µM; Fig. 2B), suggesting that oral dosing as a methyl cellulose suspension gives reproducible exposure at the lower doses.
|
MRK-560 caused a dose-dependent reduction in both brain and CSF A(40) levels (Fig. 3C), with essentially complete inhibition of the production of both peptides being observed at a dose of 100 mg/kg. The ED50 values generated for brain and CSF A(40) were 6 and 10 mg/kg, respectively, demonstrating that the effect of MRK-560 on the inhibition of the production of A(40) in brain and CSF were similar.
By plotting A(40) levels as a function of plasma and brain drug concentrations, the drug concentrations required to inhibit brain and CSF A(40) levels by 50% (EC50) were calculated (Fig. 4). For plasma, these values were found to be 1.2 µM for brain and 1.7 µM for CSF (Fig. 4A), and for brain concentrations, these values were 0.13 µM for brain and 0.19 µM for CSF (Fig. 4B), again demonstrating that inhibition of CSF A(40) paralleled brain A(40).
|
(40) Concentrations upon Acute and Chronic Dosing of MRK-560. To establish whether the pharmacodynamic response [i.e., A(40) reductions] followed plasma pharmacokinetics and to see whether reductions in the CSF and brain A(40) were maintained after chronic dosing, the time courses of CSF and brain A(40) reduction were studied after a single, acute dose as well as after chronic (2-week) dosing (Fig. 5). In keeping with the oral pharmacokinetic profile of MRK-560, the brain A(40) levels in the acute dose study (Fig. 5A) gradually decreased with the maximal reduction taking place between 16 and 24 h. The CSF levels of A(40) initially seemed to be reduced more rapidly at 4 and 8 h than the brain levels, but because a lag was not seen in the other studies conducted here, it was not deemed significant. After these time points, the brain and CSF A(40) levels followed each other closely. The overall integrated reductions across the 24-h period were very similar, with brain A(40) levels being reduced by 35% and CSF levels by 42%.
|
The pharmacokinetic data (Fig. 2) suggested that the concentrations of MRK-560 should accumulate on repeated dosing resulting in a greater reduction in A(40) levels. This effect was observed experimentally after 2-week dosing in that the levels of both CSF and brain A(40) were reduced more than in the single dose study. The overall reduction of brain A(40) was 88% in the 24-h period after the last dose. The overall reduction of CSF A(40) was 55% in the period after the last dose.
Correlation of Brain and CSF A(40). Qualitatively, changes in CSF A(40) mirror those seen in brain A(40) in both dose-response and time-course experiments (Figs. 3 and 5, respectively). To more specifically determine how well the reduction of A(40) in the CSF paralleled the brain A(40) reduction, the values for brain and CSF from the dose-response and time-course experiments were correlated using linear regression analysis (Fig. 6). The data demonstrated a significant correlation (F = 123.7; p < 0.0001).
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
in the pathogenesis of Alzheimer's disease has been demonstrated in several studies; as a result, there are currently a number of approaches to lowering A levels in the central nervous system, with one of the main focuses being -secretase inhibition (for review, see Harrison et al., 2004). Recent studies have reported bioavailable -secretase inhibitors that reduce A levels in both transgenic and nontransgenic species (Lanz et al., 2003, 2004; Anderson et al., 2005; Barten et al., 2005; Best et al., 2005).
We have previously reported a novel series of cyclohexyl sulfone -secretase inhibitors that were able to reduce A levels in SH-SY5Y cells with IC50 values in the nanomolar range (Churcher et al., 2006). Of these, compound 32 (MRK-560) caused significant reductions of brain A(40) levels in the APP-YAC mouse model, with an ED50 of 1.2 mg/kg 4 h postdosing, which compared very favorably with BMS-299897, which lowered brain A(40), with an ED50 of 30 mg/kg at 3 h in the APP-YAC mouse (Anderson et al., 2005). We have previously demonstrated that the rat is a good physiological model for assessing -secretase inhibitors (Best et al., 2005). Thus, the current study was conducted to characterize further MRK-560 in the rat and assess its effects on A(40) in the brain and CSF and to investigate the relationship between A(40) in the brain and CSF.
MRK-560 had a long half-life of >15 h in the rat, suggesting its suitability for once-a-day dosing. Furthermore, the fact that the levels of MRK-560 had not returned to zero after 24 h suggested that the compound would accumulate and therefore comparatively higher efficacy could be attained for a given dose when the compound reached steady-state levels. This profile contrasts with LY-411575, which had a very short half-life (2 h) in the rat (Best et al., 2005).
The oral pharmacokinetic profile suggested that the optimum time point for investigating A reductions was 8 to 12 h. Thus, a dose-response experiment was conducted at 8 h and demonstrated a robust dose-dependent reduction of brain A(40), with 30 mg/kg causing a complete reduction.
A number of previous studies in rodents demonstrated that changes in CSF A(40) levels correlate with brain A(40) levels (Lanz et al., 2004; Anderson et al., 2005; Barten et al., 2005; Best et al., 2005). As well as being able to study the response of -secretase inhibitors on a physiological system, another advantage of the rat is the relative ease with which CSF can be obtained, thereby allowing investigation of the relationship between changes in CSF A(40) levels and the brain A(40). The dose-response experiments revealed a similar reduction of CSF A(40) compared with brain A(40) with both the ED50 and EC50 being within 2-fold of each other. To determine whether this relationship was maintained upon repeated dosing of MRK-560, acute and subchronic time courses were conducted. In the acute dose study, maximal brain A(40) reductions were reached at 8 h and remained fairly constant up to 24 h, reflecting the pharmacokinetics of the compound. The reduction of A(40) observed at 8 h with 45 mg/kg was less than the single dose of 30 mg/kg in the dose response and is probably due to lower drug concentrations, indicating oral dosing with MRK-560 is less reproducible at higher doses. In the 2-week study, as expected, the brain and CSF A(40) levels were further reduced because of the expected accumulation of MRK-560 as a result of its long half-life. The brain A(40) levels were constant across the 24-h period, demonstrating MRK-560 suitability for once-a-day dosing regimes. Although not directly paralleling the brain levels, the profile of CSF A(40) across the 24 h was reflective of the brain levels. When all the data from the studies were correlated, a significant relationship was seen between the brain and CSF A(40) levels, confirming that CSF A(40) is a good marker of brain A(40) levels.
In addition to CSF-brain transport mechanisms, it has been demonstrated that rapid efflux of A from brain to plasma is mediated by low-density lipoprotein receptor-related protein, which also seems to be a substrate for -secretase (Shibata et al., 2000; Lleó et al., 2005). A recent study in normal human volunteers demonstrated changes in plasma A without effects on CSF A (Siemers et al., 2005). The importance of these findings reinforces the need for an assay able to measure picomolar levels of A expected in the rat plasma.
In addition to processing APP, -secretase mediates a number of other regulatory functions. One the best characterized is the Notch pathway, which has been implicated in peripheral organ toxicity (Searfoss et al., 2003; Wong et al., 2004). In a study of organ toxicity, it was demonstrated that LY-411575 caused thymus atrophy and deterioration of intestinal epithelium with accompanying weight loss after dosing for 2 weeks in transgenic mice (Wong et al., 2004). Furthermore, a 4-day dosing study with 10 mg/kg compound X revealed gross changes in the ileum, which correlated with abnormal histological changes in cell morphology (Searfoss et al., 2003). Preliminary visual inspection of the digestive system of the animals dosed for 2 weeks revealed no profound effects of MRK-560 on the ileum or effect on weight gain (data not shown). These initial findings suggest a more detailed analysis of effects of MRK-560 on the peripheral organ system is needed, because it seems that MRK-560 is able to attain substantial brain A(40) reductions without confounding side effects in the periphery.
In summary, the current study demonstrates MRK-560 as a novel, orally bioavailable -secretase inhibitor able to significantly reduce the levels of A(40) in the rat brain. Furthermore, these results confirm the use of CSF as a dependable biomarker for monitoring brain A(40) levels and further substantiate the rat as a reliable physiological model for measuring changes of A(40).
|
Footnotes |
|---|
ABBREVIATIONS: AD, Alzheimer's disease; APP, amyloid precursor protein; LY-411575, N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide; BMS-299897, 2-[(1R)-1-[[(4-chlorophenyl)sulfony](2,5-difluorophenyl) amino]ethyl]-5-fluorobenzenepropanoicacid; CSF, cerebrospinal fluid; MRK-560, N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide.
Address correspondence to: Dr. Mark Shearman, Merck Research Laboratories, 33, Avenue Louis Pasteur, Boston, MA 02115. E-mail: mark_shearman{at}merck.com
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Anderson JJ, Holtz G, Baskin PP, Turner M, Rowe B, Wang B, Kounnas MZ, Lamb BT, Barten D, Felsenstein K, et al. (2005) Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol 69: 689-698.[CrossRef][Medline]
Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, Robertson BJ, et al. (2005) Dynamics of -amyloid reductions in brain, cerebrospinal fluid and plasma of -amyloid precursor protein transgenic mice treated with a -secretase inhibitor. J Pharmacol Exp Ther 312: 635-643.
Best JD, Jay MT, Otu F, Ma J, Nadin A, Ellis S, Lewis HD, Pattison C, Reilly M, Harrison T, et al. (2005) Quantitative measurement of changes in amyloid-(40) in the rat brain and cerebrospinal fluid after treatment with the -secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]. J Pharmacol Exp Ther 313: 902-908.
Churcher I and Beher D (2005) gamma-Secretase as a therapeutic target for the treatment of Alzheimer's disease. Curr Pharm Des 11: 3363-3382.[CrossRef][Medline]
Churcher I, Beher D, Best JD, Castro JL, Clarke EE, Gentry A, Harrison T, Hitzel L, Kay E, Kerrad S, et al. (2006) 4-Substituted cyclohexyl sulfones as potent, orally-active -secretase inhibitors. Bioorg Med Chem Lett 16: 280-284.[CrossRef][Medline]
Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, et al. (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76: 173-181.[CrossRef][Medline]
Grimwood S, Hogg J, Jay MT, Lad AM, Lee V, Murray F, Peachey J, Townend T, Vithlani M, Beher D, et al. (2005) Determination of guinea-pig cortical gamma-secretase activity ex vivo following the systemic administration of a gamma-secretase inhibitor. Neuropharmacology 48: 1002-1011.[CrossRef][Medline]
Haass C (2004) Take five-BACE and the -secretase quartet conduct Alzheimer's amyloid b-peptide generation. EMBO (Eur Mol Biol Organ) J 23: 483-488.[CrossRef][Medline]
Hardy J (1997) The Alzheimer family of diseases: many etiologies, one pathogenesis? Proc Natl Acad Sci USA 94: 2095-2097.
Harrison T, Churcher I, and Beher D (2004) gamma-Secretase as a target for drug intervention in Alzheimer's disease. Curr Opin Drug Dis Dev 7: 709-719.[Medline]
Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, and Beyreuther K (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271: 22908-22914.
Kim KS, Miller DL, Sapienza VJ, Chen C-MJ, Bai C, Grundke-Iqbal I, Currie JR, and Wisniewski HM (1988) Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci Res Commun 2: 121-130.
Lanz TA, Himes CS, Pallante G, Adams L, Yamazaki S, Amore B, and Merchant KM (2003) The -secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 305: 864-871.
Lanz TA, Hosley JD, Adams WJ, and Merchant KM (2004) Studies of 
pharmacodynamics in the brain, cerebrospinal fluid and plasma in young (plaque-free) Tg2576 mice using the -secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). J Pharmacol Exp Ther 309: 49-55.
Lleó A, Waldron E, von Arnim CA, Herl L, Tangredi MM, Peltan ID, Strickland DK, Koo EH, Hyman BT, Pietrzik CU, et al. (2005) Low density lipoprotein receptor-related protein (LRP) interacts with presenilin 1 and is a competitive substrate of the amyloid precursor protein (APP) for -secretase. J Biol Chem 280: 27303-27309.
Middendorp O, Luthi U, Hausch F, and Barberis A (2004) Searching for the most effective screening system to identify cell-active inhibitors of beta-secretase. Biol Chem 385: 481-485.[CrossRef][Medline]
Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, Gao H, Higgins MA, May PC, and Ryan TP (2003) Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional -secretase inhibitor. J Biol Chem 278: 46107-46116.
Selkoe DJ (2001) Alzheimer's disease: genes, proteins and therapy. Physiol Rev 81: 741-766.
Selkoe DJ and Schenk D (2003) Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43: 545-584.[CrossRef][Medline]
Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, et al. (2000) Clearance of Alzheimer's amyloid-(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Investig 106: 1489-1499.[Medline]
Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, Ness D, and May PC (2005) Safety, tolerability and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 28: 126-132.[CrossRef][Medline]
Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee H-JJ, et al. (2004) Chronic treatment with the -secretase inhibitor LY-411575 inhibits -amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279: 12876-12882.
This article has been cited by other articles:
|
|
 |
|
  R. M. Page, K. Baumann, M. Tomioka, B. I. Perez-Revuelta, A. Fukumori, H. Jacobsen, A. Flohr, T. Luebbers, L. Ozmen, H. Steiner, et al. Generation of A 38 and A 42 Is Independently and Differentially Affected by Familial Alzheimer Disease-associated Presenilin Mutations and {gamma}-Secretase Modulation J. Biol. Chem., January 11, 2008; 283(2): 677 - 683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Goldstein, Y. Cao, T. Fiedler, J. Toyn, L. Iben, D. M. Barten, M. Pierdomenico, J. Corsa, C. V. C. Prasad, R. E. Olson, et al. Ex Vivo Occupancy of {gamma}-Secretase Inhibitors Correlates with Brain beta-Amyloid Peptide Reduction in Tg2576 Mice J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 102 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Best, D. W. Smith, M. A. Reilly, R. O'Donnell, H. D. Lewis, S. Ellis, N. Wilkie, T. W. Rosahl, P. A. Laroque, C. Boussiquet-Leroux, et al. The Novel {gamma} Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) Reduces Amyloid Plaque Deposition without Evidence of Notch-Related Pathology in the Tg2576 Mouse J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 552 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Hyde, N. A. McHugh, J. Chen, Q. Zhang, D. Manfra, A. A. Nomeir, H. Josien, T. Bara, J. W. Clader, L. Zhang, et al. Studies to Investigate the in Vivo Therapeutic Window of the {gamma}-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 Mouse J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1133 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Lanz, M. J. Karmilowicz, K. M. Wood, N. Pozdnyakov, P. Du, M. A. Piotrowski, T. M. Brown, C. E. Nolan, K. E. G. Richter, J. E. Finley, et al. Concentration-Dependent Modulation of Amyloid-beta in Vivo and in Vitro Using the {gamma}-Secretase Inhibitor, LY-450139 J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 924 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Masters and K. Beyreuther Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the A{beta} amyloid pathway Brain, November 1, 2006; 129(11): 2823 - 2839. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
